Canaccord raised the firm’s price target on GeneDx (WGS) to $100 from $70 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results but they believe the cmmpany has promising potential but some related risk including increasing competition, and price elasticity of demand issues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
- GeneDx price target lowered to $100 from $170 at Guggenheim
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
- GeneDx data could support improved coverage, says Craig-Hallum
- Natera announces commercial launch of Zenith genomics